UNCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Unicycive Therapeutics Inc (UNCY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has a promising analyst rating and potential future catalysts, the current technical indicators, lack of recent positive news, and weak financial performance do not support an immediate investment decision. The investor may consider monitoring the stock for future developments, particularly as the PDUFA date and market launch approach in 2026.
The MACD histogram is negative and contracting (-0.0425), indicating bearish momentum. RSI is neutral at 56.758, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level (6.373), with support at 6.063 and resistance at 6.682.
Analyst coverage initiated with a 'Buy' rating and a $72 price target, citing a compelling investment case due to potential market adoption of OLC, a best-in-class drug launch in Q3 2026, and TDAPA reimbursement support in 2027.
Congress trading data is also absent.
In Q3 2025, revenue remained at $0 with no growth. Net income improved by 46.75% YoY but is still negative at -$6.01M. EPS dropped by -28.26% YoY to -0.33, and gross margin remains at 0.
WestPark Capital initiated coverage with a 'Buy' rating and a $72 price target, citing significant stock appreciation potential ahead of regulatory approval and market launch in 2026.
